Ernst & Young and Dow Jones reported a notable trend: continued diversification in life sciences investments, particularly with medical devices, which saw investments skyrocket to $1 billion in 75 deals. Information technology is also an investment darling. Since California holds the life sciences crown stateside and has built a reputation for hosting innovative technology companies, the report is good news for both established and fledgling companies there.
“For more than two years, we’ve seen steady growth in the amount of venture capital invested and the promising liquidity markets — on the public exchanges for technology companies and primarily in mergers and acquisitions for healthcare companies — look to be driving investor optimism,” says Jessica Canning, director of Global Research at VentureOne. “Healthcare continues to attract nearly one-third of all venture capital dollars, and medical device companies, interestingly, are converging with biopharmaceuticals as a major draw for investors.”